Orlistat is, at present, the only pancreatic lipase inhibitor approved for the treatment of obesity; however, an array of gastrointestinal adverse effects associated with orlistat limits its tolerability. This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.